
China’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADC
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted approval to the investigational new drug (IND) application of InnoCare Pharma to initiate a trial of ICP-B794, a B7-H3 targeted antibody-drug conjugate …